ArticleInternational journal of rheumatic diseases2026
Elevated Histamine Receptor 2 and Toll-Like Receptor 7 Expression in Rheumatoid Arthritis: Insights Into Inflammatory Mechanisms and Potential Therapeutic Strategies.
Article in International journal of rheumatic diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRheumatoid arthritis (RA) is a chronic autoimmune disease characterized by persistent synovial inflammation and joint damage. Toll-like receptor 7 (TLR7), one of the innate immunity receptors, plays a role in releasing inflammatory mediators like cytokines and histamine. These mediators are crucial in inducing and maintaining chronic inflammation in the joints. This study examines the relationship between histamine receptor 2 (H2R) and TLR7 expression in peripheral blood mononuclear cells (PBMCs) and evaluates plasma levels of histamine, IL-10, and TNF-α in RA patients.
methodsThe study included 60 RA patients (22 newly diagnosed and 38 undergoing treatment) and 30 healthy controls. H2R and TLR7 gene expression in PBMCs was measured using Real-time PCR (RT-PCR), while plasma levels of histamine, TNF-α, and IL-10 were assessed using ELISA.
resultsH2R and TLR7 gene expression in PBMCs was significantly higher in RA patients than in controls (p = 0.0013, p = 0.0057), with newly diagnosed patients showing increased H2R expression compared to treated individuals (p = 0.0004). Plasma levels of histamine, TNF-α, and IL-10 were elevated in RA patients, with higher histamine and TNF-α levels in newly diagnosed cases and increased IL-10 in treated patients (p = 0.0253). Significant correlations were observed between H2R and TLR7 expression (R = 0.68, p < 0.0001) and between H2R expression and histamine levels (R = 0.34, p = 0.01).
conclusionsOur study suggests a potential link between H2R signaling and TLR7 activation in RA. The therapeutic potential of H2R inhibitors and TLR7 antagonists in mitigating RA progression warrants further investigation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.